SYHA1402 / CSPC Pharma - LARVOL DELTA

Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects. (PubMed, Neurol Ther) - P1 | "SYHA1402 administered as a single dose was well tolerated and safe over the dose range of 25-800 mg. More than 50% of the unchanged SYHA1402 was excreted in urine within the dose range of 25-100 mg."

Clinical • Journal • PK/PD data • Cardiovascular • Diabetic Neuropathy • Pain

A Study To Evaluate the Safety, Tolerance, Pharmacokinetics/Pharmacodynamics and Efficacy of SYHA1402 Tablets For the Treatment of Patients With Diabetic Peripheral Neuropathy in China (clinicaltrials.gov) - P2; N=135; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Clinical • New P2 trial • Diabetic Neuropathy • Pain

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Clinical • New P1 trial • Diabetes • Diabetic Neuropathy • Gene Therapies • Pain

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People (clinicaltrials.gov) - P1; N=54; Completed; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; Not yet recruiting ➔ Completed; Trial completion date: Oct 2020 ➔ Jan 2020; Trial primary completion date: Sep 2020 ➔ Jan 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date